PH12016500329A1 - Immuno-oncolytic therapies - Google Patents
Immuno-oncolytic therapiesInfo
- Publication number
- PH12016500329A1 PH12016500329A1 PH12016500329A PH12016500329A PH12016500329A1 PH 12016500329 A1 PH12016500329 A1 PH 12016500329A1 PH 12016500329 A PH12016500329 A PH 12016500329A PH 12016500329 A PH12016500329 A PH 12016500329A PH 12016500329 A1 PH12016500329 A1 PH 12016500329A1
- Authority
- PH
- Philippines
- Prior art keywords
- immunity
- reduces
- gene
- antibody response
- virus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361868978P | 2013-08-22 | 2013-08-22 | |
| PCT/US2014/052308 WO2015027163A1 (en) | 2013-08-22 | 2014-08-22 | Immuno-oncolytic therapies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12016500329A1 true PH12016500329A1 (en) | 2016-05-02 |
Family
ID=52484194
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12016500329A PH12016500329A1 (en) | 2013-08-22 | 2016-02-18 | Immuno-oncolytic therapies |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US11478518B2 (enExample) |
| EP (3) | EP3778897B1 (enExample) |
| JP (3) | JP6912199B2 (enExample) |
| KR (1) | KR102389240B1 (enExample) |
| CN (1) | CN105658795B (enExample) |
| AU (1) | AU2014308648B2 (enExample) |
| CA (3) | CA3213715A1 (enExample) |
| DK (2) | DK3036329T3 (enExample) |
| EA (1) | EA037582B1 (enExample) |
| ES (2) | ES2971528T3 (enExample) |
| FI (1) | FI3778897T3 (enExample) |
| HR (1) | HRP20240078T1 (enExample) |
| HU (1) | HUE066593T2 (enExample) |
| IL (1) | IL243996A0 (enExample) |
| LT (1) | LT3778897T (enExample) |
| MD (2) | MD4624C1 (enExample) |
| MX (1) | MX2016002257A (enExample) |
| NZ (1) | NZ716825A (enExample) |
| PE (1) | PE20160673A1 (enExample) |
| PH (1) | PH12016500329A1 (enExample) |
| PL (1) | PL3778897T3 (enExample) |
| PT (1) | PT3778897T (enExample) |
| RS (1) | RS65104B1 (enExample) |
| SG (1) | SG11201600960PA (enExample) |
| SI (1) | SI3778897T1 (enExample) |
| SM (1) | SMT202400047T1 (enExample) |
| WO (1) | WO2015027163A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3778897B1 (en) * | 2013-08-22 | 2023-12-20 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Immuno-oncolytic therapies |
| JP2018510143A (ja) | 2015-02-25 | 2018-04-12 | メモリアル スローン ケタリング キャンサー センター | 不活化非複製改変ワクシニアウイルスアンカラ（ｍｖａ）の固形腫瘍のための単独療法又は免疫チェックポイント遮断剤併用における使用 |
| US10548930B2 (en) | 2015-04-17 | 2020-02-04 | Memorial Sloan Kettering Cancer Center | Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors |
| US10370647B2 (en) * | 2015-07-22 | 2019-08-06 | National University Corporation Tottori University | Host regulatory factor that enhances replication and/or propagation of vaccinia virus |
| CA2996120C (en) * | 2015-09-08 | 2024-02-20 | Sillajen, Inc. | Modified oncolytic vaccinia viruses expressing a cytokine and a carboxylesterase and methods of use thereof |
| JP2018532810A (ja) | 2015-11-07 | 2018-11-08 | マルチビア インコーポレイテッド | がんの処置のための腫瘍抑制因子遺伝子治療および免疫チェックポイント治療を含む組成物 |
| BR112018016948A2 (pt) | 2016-02-25 | 2019-01-08 | Memorial Sloan Kettering Cancer Center | mva recombinante ou mva¿e3l que expressa flt3l humano e uso do mesmo como agente imunoterapêutico contra tumores sólidos |
| BR112018016949A2 (pt) | 2016-02-25 | 2019-01-08 | Memorial Sloan Kettering Cancer Center | vírus vaccinia atenuado competente em relação à replicação como deleção de timidina quinase com ou sem a expressão de flt3l ou gm-csf humano para imunoterapia de câncer |
| US12150969B2 (en) * | 2016-03-25 | 2024-11-26 | University of Pittsburgh—of the Commonwealth System of Higher Education | Synthetically enveloped virus |
| EP3254692A1 (en) * | 2016-06-10 | 2017-12-13 | Ceva Sante Animale | Multivalent recombinant spv |
| AU2017298385A1 (en) | 2016-07-19 | 2019-03-07 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Oncolytic viruses targeting STAT3 |
| KR20190059297A (ko) * | 2016-09-21 | 2019-05-30 | 스티븐 에이치. 쏜 | 고-이동성 군 박스 1 돌연변이체 |
| GB201616365D0 (en) | 2016-09-27 | 2016-11-09 | Helsingin Yliopisto | Non-genetic modification of enveloped viruses |
| CN110381997A (zh) | 2016-12-12 | 2019-10-25 | 茂体外尔公司 | 用于治疗和预防癌症和感染性疾病的包含病毒基因治疗和免疫检查点抑制剂的方法和组合物 |
| AU2018215558B2 (en) * | 2017-02-03 | 2023-05-25 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Oncolytic virus therapy |
| JP7206212B2 (ja) * | 2017-03-06 | 2023-01-17 | タラリス・セラピューティクス・インコーポレイテッド | 治療用細胞組成物の効力を決定するための方法及び組成物 |
| WO2018195552A1 (en) * | 2017-04-21 | 2018-10-25 | Sillajen, Inc. | Oncolytic vaccinia virus and checkpoint inhibitor combination therapy |
| CN111107872A (zh) | 2017-05-12 | 2020-05-05 | 纪念斯隆-凯特林癌症中心 | 有用于癌症免疫疗法的牛痘病毒突变体 |
| CN111556757A (zh) * | 2017-10-31 | 2020-08-18 | 西方溶瘤细胞有限公司 | 用于全身递送的平台溶瘤载体 |
| US11633441B2 (en) | 2017-12-01 | 2023-04-25 | Gerd Sutter | Immuno-modulated replication-efficient vaccinia virus strain |
| JP7312412B2 (ja) | 2018-01-05 | 2023-07-21 | オタワ ホスピタル リサーチ インスティチュート | 改変オルトポックスウイルスベクター |
| CA3094329A1 (en) | 2018-03-19 | 2020-02-20 | Multivir Inc. | Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer |
| KR20210032495A (ko) * | 2018-07-20 | 2021-03-24 | 안선 바이오파르마, 아이엔씨. | 암 세포, 면역 세포 및 종양 미세환경에 시알리다제의 전달 |
| WO2020056424A1 (en) | 2018-09-15 | 2020-03-19 | Memorial Sloan Kettering Cancer Center | Recombinant poxviruses for cancer immunotherapy |
| KR20210132003A (ko) * | 2018-12-21 | 2021-11-03 | 오타와 하스피털 리서치 인스티튜트 | 변형된 오르토폭스 바이러스 벡터 |
| KR20210113632A (ko) * | 2019-01-07 | 2021-09-16 | 칼리버 임뮤노쎄라퓨틱스, 인크. | 암을 치료하는 방법 |
| TW202038994A (zh) * | 2019-01-14 | 2020-11-01 | 美商醫格耐免疫治療公司 | 重組痘瘡病毒及其使用方法 |
| EP3923967A1 (en) | 2019-02-14 | 2021-12-22 | Ignite Immunotherapy, Inc. | Recombinant vaccinia virus and methods of use thereof |
| JP7326663B2 (ja) * | 2019-08-26 | 2023-08-16 | バイオノックス インコーポレイテッド | がんの処置のための活性成分としてワクシニアウイルス及びヒドロキシ尿素を含む医薬組成物 |
| WO2021076982A1 (en) * | 2019-10-16 | 2021-04-22 | KaliVir Immunotherapeutics LLC | Modified extracellular enveloped virus |
| EP4061417A4 (en) * | 2019-11-20 | 2023-10-11 | University of Pittsburgh - of the Commonwealth System of Higher Education | VACCINIA VIRUSES AND METHOD FOR USING VACCINIA VIRUSES |
| WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
| IL293627A (en) * | 2019-12-12 | 2022-08-01 | Ignite Immunotherapy Inc | Variant oncolytic vaccinia virus and methods of use thereof |
| US20230201283A1 (en) * | 2020-01-09 | 2023-06-29 | Pfizer Inc. | Recombinant vaccinia virus |
| CN115243714A (zh) * | 2020-03-06 | 2022-10-25 | 匹兹堡大学联邦系统高等教育 | 用于治疗癌症的表达irf调节剂的溶瘤病毒 |
| KR20230110545A (ko) | 2020-11-19 | 2023-07-24 | 칼리버 임뮤노쎄라퓨틱스, 인크. | 종양 미세환경 재형성에 의한 종양용해 면역요법 |
| MX2023012608A (es) * | 2021-04-30 | 2023-11-03 | Kalivir Immunotherapeutics Inc | Virus oncoliticos para la expresion modificada del mhc. |
| CA3224374A1 (en) * | 2021-06-29 | 2023-01-05 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| WO2023106839A1 (ko) * | 2021-12-07 | 2023-06-15 | 재단법인 아산사회복지재단 | Il-12를 발현하는 재조합 백시니아 바이러스 및 이의 용도 |
| WO2025251079A1 (en) * | 2024-05-31 | 2025-12-04 | University Of Massachusetts | Rna compositions and methods of use thereof in the treatment of cancer |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX9305855A (es) | 1992-09-24 | 1995-01-31 | Tadatsugu Taniguchi | Factores 1 y 2 reguladores del interferon en el diagnostico de latumorigenicidad. |
| WO2000073479A1 (en) | 1999-05-28 | 2000-12-07 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector |
| JP3986439B2 (ja) | 2001-02-07 | 2007-10-03 | 中外製薬株式会社 | 造血器腫瘍の治療剤 |
| CN101912421A (zh) * | 2002-08-12 | 2010-12-15 | 杰能斯有限公司 | 涉及痘病毒和癌的方法及组合物 |
| JPWO2007023725A1 (ja) * | 2005-08-25 | 2009-02-26 | 公立大学法人横浜市立大学 | 遺伝子ワクチン |
| AU2012244210B2 (en) * | 2005-09-07 | 2014-10-02 | Sillajen Biotherapeutics, Inc. | Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses |
| US8980246B2 (en) * | 2005-09-07 | 2015-03-17 | Sillajen Biotherapeutics, Inc. | Oncolytic vaccinia virus cancer therapy |
| US9180149B2 (en) * | 2005-09-07 | 2015-11-10 | Sillajen Biotherapeutics, Inc. | Systemic treatment of metastatic and/or systemically-disseminated cancers using GM-CSF-expressing poxviruses |
| KR20080084528A (ko) * | 2007-03-15 | 2008-09-19 | 제네렉스 바이오테라퓨틱스 인크. | 종양살상형 백시니아 바이러스 암 치료 |
| WO2009124044A2 (en) * | 2008-03-31 | 2009-10-08 | University Of Florida Research Foundation, Inc. | Tumor growth inhibition via conditioning of tumor microenvironment |
| AU2010291901C1 (en) | 2009-09-14 | 2016-03-03 | Sillajen Biotherapeutics, Inc. | Oncolytic vaccinia virus combination cancer therapy |
| US20130202639A1 (en) | 2010-03-25 | 2013-08-08 | Konstantin G. Kousoulas | Synthetic Herpes Simplex Viruses for Treatment of Cancers |
| US11149254B2 (en) * | 2011-04-15 | 2021-10-19 | Genelux Corporation | Clonal strains of attenuated vaccinia viruses and methods of use thereof |
| WO2014047350A1 (en) * | 2012-09-20 | 2014-03-27 | Morningside Technology Ventures Ltd. | Oncolytic virus encoding pd-1 binding agents and uses of the same |
| EP3778897B1 (en) | 2013-08-22 | 2023-12-20 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Immuno-oncolytic therapies |
-
2014
- 2014-08-22 EP EP20189155.3A patent/EP3778897B1/en active Active
- 2014-08-22 NZ NZ716825A patent/NZ716825A/en unknown
- 2014-08-22 JP JP2016536482A patent/JP6912199B2/ja active Active
- 2014-08-22 WO PCT/US2014/052308 patent/WO2015027163A1/en not_active Ceased
- 2014-08-22 CN CN201480058401.0A patent/CN105658795B/zh active Active
- 2014-08-22 PT PT201891553T patent/PT3778897T/pt unknown
- 2014-08-22 ES ES20189155T patent/ES2971528T3/es active Active
- 2014-08-22 AU AU2014308648A patent/AU2014308648B2/en active Active
- 2014-08-22 SI SI201432060T patent/SI3778897T1/sl unknown
- 2014-08-22 ES ES14837931T patent/ES2847305T3/es active Active
- 2014-08-22 HR HRP20240078TT patent/HRP20240078T1/hr unknown
- 2014-08-22 CA CA3213715A patent/CA3213715A1/en active Pending
- 2014-08-22 HU HUE20189155A patent/HUE066593T2/hu unknown
- 2014-08-22 MD MD20160027A patent/MD4624C1/ro active IP Right Grant
- 2014-08-22 RS RS20240082A patent/RS65104B1/sr unknown
- 2014-08-22 PL PL20189155.3T patent/PL3778897T3/pl unknown
- 2014-08-22 PE PE2016000287A patent/PE20160673A1/es unknown
- 2014-08-22 DK DK14837931.6T patent/DK3036329T3/da active
- 2014-08-22 EP EP14837931.6A patent/EP3036329B1/en active Active
- 2014-08-22 CA CA3213683A patent/CA3213683A1/en active Pending
- 2014-08-22 LT LTEP20189155.3T patent/LT3778897T/lt unknown
- 2014-08-22 SG SG11201600960PA patent/SG11201600960PA/en unknown
- 2014-08-22 EP EP23215391.6A patent/EP4324918A3/en not_active Withdrawn
- 2014-08-22 SM SM20240047T patent/SMT202400047T1/it unknown
- 2014-08-22 FI FIEP20189155.3T patent/FI3778897T3/fi active
- 2014-08-22 MX MX2016002257A patent/MX2016002257A/es unknown
- 2014-08-22 MD MDA20180086A patent/MD4748C1/ro active IP Right Grant
- 2014-08-22 DK DK20189155.3T patent/DK3778897T3/da active
- 2014-08-22 CA CA2921041A patent/CA2921041C/en active Active
- 2014-08-22 KR KR1020167006785A patent/KR102389240B1/ko active Active
- 2014-08-22 EA EA201690444A patent/EA037582B1/ru unknown
-
2016
- 2016-02-07 IL IL243996A patent/IL243996A0/en unknown
- 2016-02-18 PH PH12016500329A patent/PH12016500329A1/en unknown
- 2016-02-19 US US15/048,698 patent/US11478518B2/en active Active
-
2019
- 2019-07-19 JP JP2019133264A patent/JP7021154B2/ja active Active
-
2022
- 2022-02-03 JP JP2022015459A patent/JP7333431B2/ja active Active
- 2022-09-07 US US17/939,707 patent/US12514888B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016500329A1 (en) | Immuno-oncolytic therapies | |
| PH12017501942A1 (en) | Oncolytic adenovirus encoding a b7 protein | |
| MX2020006117A (es) | Integracion dirigida de acidos nucleicos. | |
| EP4403229A3 (en) | Expression of pten-long with oncolytic viruses | |
| EA201791443A1 (ru) | Естественные киллерные клетки и их применения | |
| AU2018273963A1 (en) | Novel oncolytic viruses for sensitizing tumor cells to killing by natural killer cells | |
| HK1254861A1 (zh) | 抗lag3抗体及其用途 | |
| MX2019007840A (es) | Celulas asesinas naturales modificadas geneticamente. | |
| MD4655B1 (ro) | Virusurile bolii de Newcastle şi utilizarea acestora | |
| MX2017015666A (es) | Agentes de anticuerpos similares al receptor de celulas t, especificos para peptidos de proteina latente de membrana 2a del virus de epstein-barr (ebv) presentado por antigeno leucocitario humano (hla). | |
| PH12021551633A1 (en) | Prostate neoantigens and their uses | |
| MX2020003798A (es) | Metodos para la purificacion de arilsulfatasa a. | |
| EA201492185A1 (ru) | Способ получения рекомбинантной идуронат-2-сульфатазы | |
| EA201991806A1 (ru) | Опухоль-селективные мутанты tata-бокса и caat-бокса | |
| WO2019202401A3 (en) | Immuno-oncolytic modified vaccinia tian tan virus and methods of treating cancer | |
| EP4628895A3 (en) | Materials and methods for treating cancer | |
| MX2019005693A (es) | Factor viii direccionado a los globulos rojos y metodo para su uso. | |
| MD4480B1 (ro) | Virus ARN oncolitic stabil genetic, metodă de producere şi de utilizare a acestuia | |
| PH12017500430A1 (en) | Solubilized enzyme and uses thereof | |
| EA201790241A1 (ru) | Эффективная селективность в отношении рекомбинантных белков | |
| RU2012111004A (ru) | Способ использования рибонуклеазы bacillus intermedius | |
| MY185846A (en) | Oncolytic adenovirus encoding a b7 protein | |
| Ouifki et al. | Mathematical Model of Tumor-Immune Surveillance | |
| EA201890595A1 (ru) | Онколитический аденовирус, кодирующий белок b7 | |
| MX2023004302A (es) | Anticuerpos anti-cd38 y fusiones con interferon alfa-2b atenuado. |